[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.176.252. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
October 13, 2004

Intrathecal Ziconotide for Chronic Pain—Reply

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2004;292(14):1681-1682. doi:10.1001/jama.292.14.1682-a

In Reply: In response to Drs Bonicalzi and Canavero, we acknowledge that our short trial cannot be considered the sole method of validating the long-term efficacy of intrathecal ziconotide. Our design, however, provided sufficient time to determine that ziconotide provided effective pain relief with minimal adverse effects and to offer our participants continued pain management using the novel agent in a second, open-label, compassionate trial, during which we continued to collect safety and efficacy data.

×